Current developments in cancer vaccines and cellular immunotherapy
- PMID: 12805342
- DOI: 10.1200/JCO.2003.06.041
Current developments in cancer vaccines and cellular immunotherapy
Abstract
This article reviews the immunologic basis of clinical trials that test means of tumor antigen recognition and immune activation, with the goal to provide the clinician with a mechanistic understanding of ongoing cancer vaccine and cellular immunotherapy clinical trials. Multiple novel immunotherapy strategies have reached the stage of testing in clinical trials that were accelerated by recent advances in the characterization of tumor antigens and by a more precise knowledge of the regulation of cell-mediated immune responses. The key steps in the generation of an immune response to cancer cells include loading of tumor antigens onto antigen-presenting cells in vitro or in vivo, presenting antigen in the appropriate immune stimulatory environment, activating cytotoxic lymphocytes, and blocking autoregulatory control mechanisms. This knowledge has opened the door to antigen-specific immunization for cancer using tumor-derived proteins or RNA, or synthetically generated peptide epitopes, RNA, or DNA. The critical step of antigen presentation has been facilitated by the coadministration of powerful immunologic adjuvants, the provision of costimulatory molecules and immune stimulatory cytokines, and the ability to culture dendritic cells. Advances in the understanding of the nature of tumor antigens and their optimal presentation, and in the regulatory mechanisms that govern the immune system, have provided multiple novel immunotherapy intervention strategies that are being tested in clinical trials.
Similar articles
-
Tumor antigens and tumor vaccines: peptides as immunogens.Semin Surg Oncol. 1996 Nov-Dec;12(6):446-53. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T. Semin Surg Oncol. 1996. PMID: 8914209 Review.
-
Advances in specific immunotherapy for prostate cancer.Eur Urol. 2008 Apr;53(4):694-708. doi: 10.1016/j.eururo.2007.11.043. Epub 2007 Nov 26. Eur Urol. 2008. PMID: 18061335 Review.
-
Antitumor vaccination: where we stand.Haematologica. 2000 Nov;85(11):1172-206. Haematologica. 2000. PMID: 11074658 Review.
-
Immunotherapy of metastasis.Surg Oncol Clin N Am. 2001 Apr;10(2):433-47, xi. Surg Oncol Clin N Am. 2001. PMID: 11382596 Review.
-
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Immunol Rev. 2008. PMID: 18364008 Review.
Cited by
-
Use of immunotherapy in the treatment of gastric cancer.Oncol Lett. 2019 Dec;18(6):5681-5690. doi: 10.3892/ol.2019.10935. Epub 2019 Sep 30. Oncol Lett. 2019. PMID: 31788040 Free PMC article. Review.
-
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.J Transl Med. 2010 Nov 10;8:116. doi: 10.1186/1479-5876-8-116. J Transl Med. 2010. PMID: 21067607 Free PMC article.
-
KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6. J Clin Invest. 2008. PMID: 19033668 Free PMC article.
-
Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.Cancer Immunol Immunother. 2010 Jan;59(1):113-24. doi: 10.1007/s00262-009-0730-7. Epub 2009 Jun 27. Cancer Immunol Immunother. 2010. PMID: 19562340 Free PMC article.
-
Biology of human cutaneous melanoma.Cancers (Basel). 2010 Mar 12;2(1):165-89. doi: 10.3390/cancers2010165. Cancers (Basel). 2010. PMID: 24281039 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources